Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 0.71 |
| ▸ | CCND1 | P24385 | 14/20 | 0.71 |
| ▸ | CCND2 | P30279 | 8/20 | 0.71 |
| ▸ | CCND3 | P30281 | 8/20 | 0.71 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.71 |
| ▸ | CDK2 | P24941 | 6/20 | 0.71 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.71 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.71 |
| ▸ | FGFR4 | P22455 | 6/20 | 0.71 |
| ▸ | FGFR3 | P22607 | 6/20 | 0.71 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.71 |
| ▸ | CDK6 | Q00534 | 7/20 | 0.66 |
| ▸ | CDK1 | P06493 | 1/20 | 0.64 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.64 |
| ▸ | FLT3 | P36888 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344501 | 0.88 | CDK4 (0.69) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL1356055 | 0.88 | CDK4 (0.69) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL12639351 | 0.88 | CDK4 (0.60) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL22113094 | 0.86 | CDK4 (0.62) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL11976961 | 0.84 | CDK4 (0.71) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL30297622 | 0.84 | CDK4 (0.71) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL7706831 | 0.83 | CDK4 (0.72) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL4830882 | 0.83 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL29507526 | 0.83 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CCNA2 | |
| Hydrochloric Acid SCHEMBL4833048 | 0.82 | CDK4 (0.98) | CDK4CCND1CCND2CCND3CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947695-B2 | Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-7947695-B2 | Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-20080070914-A1 | Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent | JANSSEN-CILAG (FR) | 2008-03-20 | — | — | US | disclosed |
| US-20080070914-A1 | Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent | JANSSEN-CILAG (FR) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070914-A1 | Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent | CDK1, CDK2, CDK4 | CDK4 3/4885CCND1 34/4885CCND2 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.